Halozyme Therapeutics Inc (HALO)
44.71
-0.68
(-1.50%)
USD |
NASDAQ |
May 17, 16:00
44.73
+0.02
(+0.04%)
Pre-Market: 20:00
Halozyme Therapeutics Accounts Receivable (Quarterly): 191.52M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 191.52M |
December 31, 2023 | 240.00M |
September 30, 2023 | 219.92M |
June 30, 2023 | 228.09M |
March 31, 2023 | 200.80M |
December 31, 2022 | 188.88M |
September 30, 2022 | 155.92M |
June 30, 2022 | 161.94M |
March 31, 2022 | 115.00M |
December 31, 2021 | 92.12M |
September 30, 2021 | 113.30M |
June 30, 2021 | 154.52M |
March 31, 2021 | 89.50M |
December 31, 2020 | 98.73M |
September 30, 2020 | 63.79M |
June 30, 2020 | 38.25M |
March 31, 2020 | 30.69M |
December 31, 2019 | 60.24M |
September 30, 2019 | 41.33M |
June 30, 2019 | 32.89M |
March 31, 2019 | 28.80M |
December 31, 2018 | 30.60M |
September 30, 2018 | 28.16M |
June 30, 2018 | 33.58M |
March 31, 2018 | 27.07M |
Date | Value |
---|---|
December 31, 2017 | 22.69M |
September 30, 2017 | 15.20M |
June 30, 2017 | 15.05M |
March 31, 2017 | 13.03M |
December 31, 2016 | 16.24M |
September 30, 2016 | 18.07M |
June 30, 2016 | 24.04M |
March 31, 2016 | 26.22M |
December 31, 2015 | 33.38M |
September 30, 2015 | 9.126M |
June 30, 2015 | 10.56M |
March 31, 2015 | 8.597M |
December 31, 2014 | 9.76M |
September 30, 2014 | 9.147M |
June 30, 2014 | 13.49M |
March 31, 2014 | 11.68M |
December 31, 2013 | 9.707M |
September 30, 2013 | 24.52M |
June 30, 2013 | 11.03M |
March 31, 2013 | 10.38M |
December 31, 2012 | 15.88M |
September 30, 2012 | 4.464M |
June 30, 2012 | 5.687M |
March 31, 2012 | 5.551M |
December 31, 2011 | 2.262M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
30.69M
Minimum
Mar 2020
240.00M
Maximum
Dec 2023
125.87M
Average
114.15M
Median
Accounts Receivable (Quarterly) Benchmarks
Novavax Inc | 21.38M |
Globus Medical Inc | 534.33M |
Denali Therapeutics Inc | -- |
AIM ImmunoTech Inc | -- |
Protalix BioTherapeutics Inc | 3.759M |